India should remain on 301 ‘Priority Watch List’, says PhRMA

09-02-2016

India should remain on 301 ‘Priority Watch List’, says PhRMA

SOMMAI / Shutterstock.com

India’s weak intellectual property enforcement regime and its vague grounds centring on compulsory licences for drugs are reasons it should remain on the “Priority Watch List” in this year’s "Special 301 Report", a pharmaceutical industry association has argued.


301 Priority Watch List; USTR; PhRMA; compulsory licences; Narendra Modi

More on this story

Indian drug makers end generic bids
18-04-2016

LSIPR